[CAS NO. 2320274-72-2] ST-193 hydrochloride
PRODUCTS SPECIFICATIONS [2320274-72-2]
DESCRIPTION [2320274-72-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 407.94 |
| Molecular Formula | C24H26ClN3O |
| SMILES | CC(C1=CC=C(CNC2=CC=C3C(N=CN3C4=CC=C(OC)C=C4)=C2)C=C1)C.[H]Cl |
4 Publications Citing Use of MCE
Summary
ST-193 hydrochloride is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC 50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
IC50 & Target
IC50: 0.44 nM (Guanarito), 0.62 nM (Junin), 1.4 nM (Lassa) and 3.1 nM (Machupo) [1]
In Vitro
ST-193 inhibits LASV pseudotypes with an IC 50 of 1.6 nM. ST-193 inhibits pseudotypes generated with other arenavirus envelopes as well, including the remaining four commonly associated with hemorrhagic fever (IC 50 s for Junín, Machupo, Guanarito, and Sabiá are in the 0.2 to 12 nM range) but exhibits no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus lymphocytic choriomeningitis virus or the unrelated G protein from vesicular stomatitis virus, at concentrations of up to 10 μM [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ST-193 is found to be tolerated well when administered daily as an intraperitoneal injection of either 25 or 100 mg/kg/day for 14 days. ST-193-treated animals exhibit fewer signs of disease and enhance survival when compared to the ribavirin or vehicle groups. Body temperatures in all groups are elevated by day 9, but returned to normal by day 19 postinfection in the majority of ST-193-treated animals. ST-193 treatment mediates a 2- to 3-log reduction in viremia relative to vehicle-treated controls. The overall survival rate for the ST-193-treated guinea pigs is 62.5% (10/16) compared with 0% in the ribavirin (0/8) and vehicle (0/7) groups [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 150 mg/mL ( 367.70 mM )
H 2 O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4513 mL | 12.2567 mL | 24.5134 mL |
| 5 mM | 0.4903 mL | 2.4513 mL | 4.9027 mL |
| 10 mM | 0.2451 mL | 1.2257 mL | 2.4513 mL |
References
- [1] Burgeson JR, et al. Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. Bioorg Med Chem Lett. 2013 Feb 1;23(3):750-6.
- [2] Larson RA, et al. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008 Nov;82(21):10768-75.
- [3] Cashman KA, et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011 Apr;90(1):70-9.